未经批准:这项研究估计,沙特阿拉伯,将患者从参考Neupogen1和Neulastim转换为两种非格司亭生物仿制药之一的成本效率(Nivestim,Zarzio);预算中立的人通过生物仿制药非格司亭和治疗性护理扩大了获得支持性护理的机会,从而提供了ado-trastuzumabemtansine;以及为一名患者提供支持性或治疗性治疗所需的数量转换(NNC)。
未经评估:复制先前的研究,我们模拟了通过将接受6个周期癌症治疗的4000名患者的不同比例从Neupogen或Neulastim转换为两种生物仿制药G-CSF制剂之一而获得的成本效益。利用国家成本投入。以美元为单位的成本节约用于估计生物仿制药G-CSF的额外剂量,并在预算中立的基础上扩大对ado-曲妥珠单抗emtansine的使用,和NNC购买额外剂量的支持性或治疗性治疗。
UNASSIGNED:从参考转换为生物仿制药的节省为3,086,400美元(Nivestime2)和3,460,800美元(Zarzio)。参考pegfilgrastim,转换节省了11,712,240美元(Nivestim)和12,086,640美元(Zarzio)。生物类似药从生物类似药非格司亭的转换使61名患者扩大了对ado-曲妥珠单抗emtansine的访问(5天,Nivestim)对191名患者(14天,Zarzio)。对于支持性护理,生物仿制药的转换使8244名患者(5天,Nivestim)对25,882名患者(14天,Zarzio)。对于每日非格司亭的生物仿制药转化,随着注射天数的增加,用ado-曲妥珠单抗emtansine治疗的NNC降低[5天:395(Nivestim),352(Zarzio);14天:141(Nivestim),126(Zarzio)]。或者,从单次注射pegfilgrastim到每日生物相似物filgrastim的生物相似物转化,随着注射天数的增加,用ado-曲妥珠单抗emtansine治疗的NNC上升,在14天情景下最高(146,Nivestim;130,Zarzio)。
UNASSIGNED:这项模拟研究显示了生物仿制药转化带来的巨大潜在成本节约。这些节省提供了预算中立的更多获得支持性和治疗性癌症护理的机会。
UNASSIGNED: This
study estimated, for Saudi Arabia, the cost-efficiency of converting patients from reference Neupogen and Neulastim to one of two filgrastim biosimilars (Nivestim, Zarzio); the budget-neutral expanded access to supportive care with biosimilar filgrastim and therapeutic care to ado-trastuzumab emtansine thus afforded; and the number-needed-to-convert (NNC) to provide supportive or therapeutic treatment to one patient.
UNASSIGNED: Replicating prior studies, we modeled the cost-efficiencies gained from converting varying proportions of a hypothetical panel of 4,000 patients undergoing six cycles of cancer treatment from Neupogen or Neulastim to one of the two biosimilar G-CSF formulations, using national cost inputs. Cost-savings in USD were used to estimate the additional doses of biosimilar G-CSF and expanded access to ado-trastuzumab emtansine on a budget-neutral basis, and NNC to purchase one additional dose of supportive or therapeutic treatment.
UNASSIGNED: Savings from conversion from reference to a biosimilar filgrastim were $3,086,400 (Nivestim) and $3,460,800 (Zarzio). With reference
pegfilgrastim, savings from conversion were $11,712,240 (Nivestim) and $12,086,640 (Zarzio). Biosimilar conversion from reference to biosimilar filgrastim enabled expanded access to ado-trastuzumab emtansine ranging from 61 patients (5 days, Nivestim) to 191 patients (14 days, Zarzio). For supportive care, biosimilar conversion enabled expanded access ranging from 8,244 patients (5 days, Nivestim) to 25,882 patients (14 days, Zarzio). For biosimilar conversion from daily filgrastim, the NNC for treatment with ado-trastuzumab emtansine decreased as days of injections increased [5 days: 395 (Nivestim), 352 (Zarzio); 14 days: 141(Nivestim), 126 (Zarzio)]. Alternately, for biosimilar conversion from single-injection
pegfilgrastim to daily biosimilar filgrastim, the NNC for treatment with ado-trastuzumab emtansine rose as days of injections increased, being highest under the 14-day scenario (146, Nivestim; 130, Zarzio).
UNASSIGNED: This simulation
study demonstrated significant potential cost-savings from biosimilar conversion. These savings provide budget-neutral increased access to supportive and therapeutic cancer care.